ArticleBrain and behavior2025
Jiawei Kongsheng Zhenzhong Pill (JKZP) Alleviates Chronic Cerebral Hypoperfusion-Induced Hippocampal Synaptic Damage via S100A10/tPA/BDNF Pathway.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neurotrophin System Alterations Associated with Neurotoxicity Accompanied by Carotid Artery Diseases-A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Traditional Chinese medicines alleviate experimental chronic cerebral hypoperfusion injury through multi-components and multi-target mechanisms.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsTo evaluate the effects of Jiawei Kongsheng Zhenzhong Pill (JKZP) on rats with ischemic mild cognitive impairment (MCI) and investigate the underlying mechanisms.
methodsThe components of JKZP were analyzed using Q-Orbitrap high-resolution mass spectrometry (HRMS). The MCI rat model was prepared through gradual bilateral common carotid artery occlusion (BCCAO). The cognitive function, hippocampal pathological lesions, dendritic spine damage, synapse-related, and S100 calcium-binding protein A10 (S100A10)/tissue-type plasminogen activator (tPA)/brain-derived neurotrophic factor (BDNF) pathway-associated molecules alterations were measured. Primary hippocampus neurons were subjected to oxygen-glucose deprivation/reperfusion (OGD/R) injury, and JKZP-containing serum was utilized for treatment. Lentiviral-infected neurons were constructed with S100A10 knockdown using RNAi technology to investigate whether JKZP exerted its anti-MCI effects via S100A10/tPA/BDNF pathway.
resultsA total of 64 major components, including β-asarone, ferulic acid, loganin, senkyunolide H, and cryptotanshinone, were identified by Q-Orbitrap HRMS technology. JKZP had a notable impact on enhancing the cognitive abilities of rats with MCI. JKZP reduced the damage to the hippocampal CA1 region neuron and synaptic structure, reversed the decrease in dendritic spines, and increased the expressions of synapse-associated proteins such as synaptophysin (SYN), growth-associated protein 43 (GAP43), and postsynaptic density protein 95 (PSD95). Furthermore, JKZP treatment dramatically reduced the ratio of protein of BDNF (proBDNF)/mature BDNF (mBDNF) by activating S100A10/tPA, which was confirmed in primary hippocampus neurons in vitro. Moreover, sh-S100A10 tremendously mitigated the inhibitory action of JKZP on OGD/R-mediated synapse injury, decreased the activity of tPA, and thus improved the downstream pathway targets' ratio, proBDNF/mBDNF.
conclusionsThese results manifested that JKZP promoted neurological recovery after chronic cerebral ischemia by alleviating synaptic damage and activating the S100A10/tPA/BDNF pathway, thereby providing a novel perspective and a solid foundation against MCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.